Business Context and Reporting Period
Company: Modular Medical, Inc. (MODD)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended June 30, 2026
Business Overview: A commercial-stage medical device company developing innovative insulin pumps. The company recently received FDA clearance for its "Pivot" patch pump in April 2026 and commenced initial shipments in June 2026. The company operates as a single reporting segment.
Key Financial Metrics
| Metric | Q2 2026 | Q2 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(6,486,000) | $(6,702,000) |
| Net Loss Per Share (Basic/Diluted) | $(1.19) | $(3.70) |
| Cash and Cash Equivalents (End of Period) | $3,920,000 | $7,522,000 |
| Operating Cash Flow | $(5,972,000) | $(5,372,000) |
| Financing Cash Flow | $3,638,000 | $733,000 |
| Total Assets | $12,253,000 | $14,832,000 (Mar 31, 2026) |
| Accumulated Deficit | $(119,481,000) | $(91,455,000) (Jun 30, 2025) |
Note: The filing does not provide revenue figures as the company has not yet generated significant commercial revenue. Margins are not applicable due to zero revenue.
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses decreased by $266,000 (3.9%) to $6.538 million.
- R&D Expenses: Decreased by $763,000 (14.9%) to $4.371 million, driven by reduced personnel costs following a reduction in force in March 2026, lower stock-based compensation, and reduced consulting/material costs.
- SG&A Expenses: Increased by $497,000 (29.8%) to $2.167 million, primarily due to higher sales and marketing expenses and professional fees.
- Liquidity: Cash and cash equivalents decreased by $3.022 million during the quarter, compared to a decrease of $5.573 million in the prior year period. This improvement in cash burn was offset by significant financing activities.
- Capital Structure: The company completed a 1-for-30 reverse stock split effective March 31, 2026. All share data in the filing has been restated to reflect this split.
Guidance, Outlook, and Risks
- Going Concern: The company has expressed substantial doubt about its ability to continue as a going concern for at least one year from the date of issuance. The independent auditor has also expressed this doubt. The company has an accumulated deficit of approximately $119.5 million and expects to continue incurring losses.
- Capital Raising: Future operations depend on raising additional capital.
- April 2026: Completed a registered direct offering raising net proceeds of approximately $3.0 million.
- June 2026: Commenced an "at-the-market" (ATM) offering program with Maxim Group LLC. Raised approximately $0.7 million during the quarter.
- Subsequent Event: Post-period (after June 30, 2026), the company raised an additional $5.1 million under the ATM program.
- Commercialization: The company is actively expanding commercial activities for its "Pivot" product in metropolitan markets and seeking foreign regulatory clearance. It expects R&D expenses to remain consistent for the remainder of fiscal 2027 but anticipates SG&A expenses to increase to support commercialization.
- Risks: Key risks include the inability to secure additional financing on acceptable terms, potential dilution to existing shareholders, and the uncertainty of market acceptance for its insulin pump products.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $3.9 million cash balance (plus subsequent $5.1 million ATM proceeds) against the current burn rate of approximately $6 million per quarter.
- Revenue Recognition: Confirm the timeline for when commercial shipments of the "Pivot" pump will translate into recognized revenue, given the current $0 revenue status.
- Dilution Impact: Assess the impact of the 1-for-30 reverse stock split and the ongoing ATM offering on share count and per-share value.
- Regulatory Status: Monitor the progress of foreign regulatory approvals for the Pivot product, which is critical for market expansion.
- Related Party Transactions: Review the royalty agreement with the founder (5% of gross sales or $0.75 per unit, capped at $10 million) and compensation paid to family members of executives.